NSCLC splits into five biomarker-defined segments, and 51% of US patients are diagnosed only after the disease reaches distant stage.

Non-small cell lung cancer is not one disease to size. Adenocarcinoma accounts for roughly 40% of all lung cancers, squamous cell carcinoma for 25 to 30%, and large cell carcinoma for about 10%. Within that histology map sits the segmentation that actually drives treatment: EGFR, ALK, ROS1, KRAS G12C, and PD-L1 expression tier, each carrying a different first-line standard of care, and sizing the wrong one is the most common pre-launch error. The US will see an estimated 229,410 new lung cancer diagnoses in 2026, and non-small cell histology accounts for roughly 85% of them.

Fifty-one percent of cases present at distant stage against just 24% localized, based on SEER 2016-2022 diagnosis data, and the biomarker-driven segment map only helps a patient whose disease is caught before it reaches that point. EGFR, ALK, KRAS G12C, and PD-L1 prevalence vary meaningfully across US and North American cohorts, and the diagnosis-to-treatment pathway loses patients between tissue-NGS or liquid-biopsy testing and the point first-line therapy actually starts, with turnaround time and guideline-complete testing rate the two levers that matter most for commercial modelling.

Sizing the wrong biomarker segment is the most common pre-launch NSCLC error.

Five questions this report answers:

Q1 - How does NSCLC segment by histology and actionable biomarker, and what governs treatment choice in each?

Q2 - How many patients present early enough for that segmentation to matter?

Q3 - What share of NSCLC actually carries each actionable biomarker?

Q4 - Which US centers and trial networks define practice and generate the evidence base?

Q5 - Where does the diagnosis-to-treatment pathway lose patients, and how fast does it move?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#NSCLC #LungCancer #Biomarkers #PrecisionOncology #DiseaseLandscape #USMarket

Live report page:  https://axlrx.ai/nsclc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/